Effects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers

Background  The mechanism of action of bisacodyl in the unprepared human colon remains unclear.

[1]  A. Zinsmeister,et al.  Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[2]  D. Miskovic,et al.  Effect of bisacodyl on postoperative bowel motility in elective colorectal surgery: a prospective, randomized trial , 2008, International Journal of Colorectal Disease.

[3]  Myung-Gyu Choi,et al.  Measurement of colonic transit using a delayed-release capsule containing radio-opaque markers , 2008, Scandinavian journal of gastroenterology.

[4]  A. Zinsmeister,et al.  Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. , 2007, Gastroenterology.

[5]  M. Kamm,et al.  Efficacy and safety of bisacodyl in the acute treatment of constipation: a double‐blind, randomized, placebo‐controlled study , 2006, Alimentary pharmacology & therapeutics.

[6]  Michael Camilleri,et al.  Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[7]  Satish S C Rao,et al.  Efficacy and Safety of Traditional Medical Therapies for Chronic Constipation: Systematic Review , 2005, The American Journal of Gastroenterology.

[8]  S. Hervé,et al.  Results of 24‐h manometric recording of colonic motor activity with endoluminal instillation of bisacodyl in patients with severe chronic slow transit constipation , 2004, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[9]  M. Samsom,et al.  Effects of a Meal and Bisacodyl on Colonic Motility in Healthy Volunteers and Patients with Slow-Transit Constipation , 2003, Digestive Diseases and Sciences.

[10]  M. Camilleri,et al.  Performance characteristics of scintigraphic transit measurements for studies of experimental therapies , 2002, Alimentary pharmacology & therapeutics.

[11]  A. Zinsmeister,et al.  Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. , 2001, Gastroenterology.

[12]  M. Camilleri,et al.  Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. , 2000, Gastroenterology.

[13]  F. Pace,et al.  Tegaserod, a 5-HT4 receptor partial agonist, relieves key symptoms of irritable bowel syndrome (IBS) , 2000 .

[14]  M. Camilleri,et al.  Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial , 2000, The Lancet.

[15]  T. Hermann,et al.  Is bisacodyl absorbed at all from suppositories in man? , 2000, International journal of pharmaceutics.

[16]  A. Morelli,et al.  Endoluminal Instillation of Bisacodyl inPatients with Severe (Slow Transit Type)Constipation Is Useful to Test Residual ColonicPropulsive Activity , 1999, Digestion.

[17]  R. N. Ratnaike,et al.  Mechanisms of Drug-Induced Diarrhoea in the Elderly , 1998, Drugs & aging.

[18]  M. Camilleri,et al.  Colonic transit scintigraphy labeled activated charcoal compared with ion exchange pellets. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  K. Ewe,et al.  Eflect of lactose, lactulose and bisacodyl on gastrointestinal transit studied by metal detector , 1995, Alimentary pharmacology & therapeutics.

[20]  A. Izzo,et al.  Nitric oxide as a mediator of bisacodyl and phenolphthalein laxative action: induction of nitric oxide synthase. , 1994, The Journal of pharmacology and experimental therapeutics.

[21]  M. Camilleri,et al.  Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. , 1993, The New England journal of medicine.

[22]  M. Camilleri,et al.  Towards a relatively inexpensive, noninvasive, accurate test for colonic motility disorders. , 1992, Gastroenterology.

[23]  M. Camilleri,et al.  Scintigraphic measurement of regional gut transit in idiopathic constipation. , 1991, Gastroenterology.

[24]  L. Melton,et al.  Assessment of functional gastrointestinal disease: the bowel disease questionnaire. , 1990, Mayo Clinic proceedings.

[25]  M. Camilleri,et al.  Transit of solids through the human colon: regional quantification in the unprepared bowel. , 1990, The American journal of physiology.

[26]  M Granowska,et al.  Dynamic scanning defines a colonic defect in severe idiopathic constipation. , 1988, Gut.

[27]  W. Roth,et al.  [Pharmacokinetics and laxative effect of bisacodyl following administration of various dosage forms]. , 1988, Arzneimittel-Forschung.

[28]  É. Gruber,et al.  The influence of bisacodyl and deacetylbisacodyl on mucus secretion, mucus synthesis and electrolyte movements in the rat colon in vivo. , 1985, European journal of pharmacology.

[29]  S. Phillips,et al.  Capacity of the human colon to absorb fluid , 1978 .

[30]  R. Smallwood,et al.  The effect of stimulation on the myoelectrical activity of the rectosigmoid in man , 1974, Gut.

[31]  W. Forth,et al.  The hydragogue and laxative effect of the sulfuric acid ester and the free diphenol of 4,4′-dihydroxydiphenyl-(pyridyl-2)-methane , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[32]  K. Ewe.  Effect of bisacodyl on intestinal electrolyte and water net transport and transit. Perfusion studies in men. , 1987, Digestion.

[33]  J. Schang,et al.  Changes in colonic myoelectric spiking activity during stimulation by bisacodyl. , 1986, Canadian journal of physiology and pharmacology.

[34]  G. Nell,et al.  Mechanism of action of diphenolic laxatives: the role of adenylate cyclase and mucosal permeability. , 1984, Digestion.

[35]  S. Phillips,et al.  Capacity of the human colon to absorb fluid. , 1978, Gastroenterology.